Bromazolam is a Schedule I controlled substance at the federal level in the United States, effective March 16, 2026. The DEA issued a temporary scheduling order placing bromazolam and its salts and isomers into Schedule I of the Controlled Substances Act, the most restrictive category. Before this federal action, several states had already scheduled it independently.
Federal Scheduling Timeline
For years, bromazolam occupied a legal gray area. It was not listed in any schedule under the Controlled Substances Act, which meant it technically wasn’t federally illegal to possess in the same way as other benzodiazepines like alprazolam or diazepam. That changed when the DEA determined bromazolam posed “an imminent hazard to the public’s safety” and placed it into Schedule I through a temporary order published in the Federal Register on March 16, 2026.
The temporary placement lasts two years, through March 16, 2028, with a possible one-year extension while the DEA works through the permanent scheduling process. Schedule I classification means the federal government considers bromazolam to have a high potential for abuse, no accepted medical use, and no accepted safety profile even under medical supervision. Possession, distribution, and manufacture now carry the same federal penalties as other Schedule I substances.
No Approved Medical Use
Bromazolam has never been approved by the FDA for any medical condition. There are no approved new drug applications and no active investigational new drug applications for it. The Department of Health and Human Services confirmed this position twice, in June 2024 and again in July 2025, during the review process that led to scheduling. Unlike prescription benzodiazepines such as alprazolam (Xanax) or lorazepam (Ativan), bromazolam was never developed as a pharmaceutical product. It was first synthesized in the 1970s during benzodiazepine research but was never brought to market.
State Laws Before Federal Action
Before the DEA acted, a handful of states moved to schedule bromazolam on their own. Nevada, New Mexico, North Dakota, Virginia, and West Virginia all designated it as a Schedule I controlled substance at the state level. Kentucky was also pursuing scheduling, noting that bromazolam had been detected in 48 overdose deaths in that state during 2024 alone. If you’re in a state that scheduled bromazolam before the federal order, those state laws remain in effect alongside the new federal classification.
How Bromazolam Entered the U.S.
Bromazolam first appeared on the illicit market in Europe, with Swedish authorities documenting the first seizure in 2016. It reached the United States by 2019. Since then, it has become one of the most common designer benzodiazepines found in the unregulated drug supply. It’s typically sold as a powder, in counterfeit pills made to look like prescription benzodiazepines, or dissolved in liquid solutions marketed as “research chemicals.”
Why It’s Considered Dangerous
Bromazolam acts on the same brain receptors as prescription benzodiazepines, producing sedation, anxiety reduction, and muscle relaxation. But because it has never been through clinical trials, there’s no established safe dose, and the potency of street supplies varies unpredictably.
The real danger shows up in overdose data. A study examining deaths in San Francisco found 44 bromazolam-related fatalities in 2023 alone, a sudden surge that outpaced deaths from all other designer benzodiazepines. Nearly all of those deaths involved other drugs, primarily fentanyl, along with stimulants like methamphetamine and cocaine. Blood concentrations of bromazolam in these cases increased over time, suggesting the supply was becoming more concentrated. The victims were predominantly male, and a significant proportion were unhoused.
The combination of bromazolam with opioids is especially lethal because both classes of drugs suppress breathing. When someone takes fentanyl laced with bromazolam (or vice versa), naloxone, the standard opioid overdose reversal drug, can reverse the opioid effects but does nothing to counteract the benzodiazepine.
Detection on Drug Tests
Standard urine drug screens can detect bromazolam in some cases, but results aren’t reliable. Lab testing has shown that bromazolam does cross-react with benzodiazepine immunoassay kits, meaning it can trigger a positive result on a routine panel. However, cross-reactivity depends on the specific test kit, the concentration in the sample, and the cutoff threshold used. A negative result on a standard screen doesn’t rule out bromazolam use. Confirmatory testing using more advanced methods like liquid chromatography-mass spectrometry is needed for definitive identification, and many hospital and workplace labs don’t routinely test for it unless specifically requested.